

MAR 04 2009

sanofi pasteur

The vaccines division of sanofi-aventis Group

Fax

To:
Examiner Devi, Sarvamangala J N
USPTO Art Unit 1645
Fax: 571-273-8300
Total Number of Pages (including this page) : 13

From:
Thomas J. Bordner
IP
Tel.: 570-957-3036
Email: thomas.bordner@sanofipasteur.com

Appl. No. : 10/054,638 Confirmation No.: 9398
Applicant : Robert P. Ryall
Filed : 22 January 2002
TC/A.U. : 1645
Docket No. : API-01-059-US
Examiner : Devi, Sarvamangala J N
Title : Multivalent Meningococcal Polysaccharide Protein Conjugate Vaccine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Via Facsimile 571-273-8300

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION
MAILED 4 SEPTEMBER 2008**

Dear Examiner:

In response to the Office Action mailed 4 September 2008 please amend the above-identified application as follows.

Best regards,



Thomas J. Bordner

**RECEIVED
CENTRAL FAX CENTER**

005/013

MAR 04 2009**Patent**

U.S. Ser. No.: 10/054,638

Response to the Office Action mailed 4 September 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/054,638 Confirmation No.: 9398
Applicant : Robert P. Ryall
Filed : 22 January 2002
TC/A.U. : 1645
Docket No. : API-01-059-US
Examiner : Devi, Sarvamangala J N
Title : Multivalent Meningococcal Polysaccharide Protein Conjugate Vaccine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Via Facsimile 571-273-8300

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION
MAILED 4 SEPTEMBER 2008**

Dear Examiner:

In response to the Office Action mailed 4 September 2008 please amend the above-identified application as follows.

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.